The landscape of metabolic research has been fundamentally transformed by glucagon-like peptide-1 (GLP-1) receptor agonists. In 2026, semaglutide remains the focal point of intense scientific inquiry, not merely for its well-documented effects on adiposity, but for its expanding role across diverse physiological systems [1]. As a synthetic analog of human GLP-1, semaglutide shares 94% structural […]
